Professor Jeremy Chataway MA, PhD, FRCP is consultant neurologist at National Hospital for Neurology and Neurosurgery (NHNN), Queen Square, UCLH and professor of neurology, University College London.
After qualifying in medicine at Cambridge and Oxford Universities, and general medical training in London, he specialised in Neurology with posts in Edinburgh, Cambridge and London. He was awarded a PhD from Cambridge University in genetic epidemiology of multiple sclerosis and took up his post as a consultant neurologist in 2001 at The National Hospital for Neurology and Neurosurgery, Queen Square, UCLH.
His clinical interest at UCLH in multiple sclerosis (MS).
He has a particular interest in advanced clinical trial design in progressive MS and was the chief investigator (CI) of the MS-STAT1 trial in secondary progressive MS, using high dose simvastatin; and is the CI of the MS-SMART (MS-SMART trial: Lancet Neurology Jan 2020 https://doi.org/10.1016/S1474-4422(19)30485-5) and MS-STAT2 (still recruiting) trials in secondary progressive MS. He works closely with the MRC Clinical Trials Unit and the UK MS Society.
Separately, he was a Founder member of the Queen Square Adult Onset Leukodystrophy Group, studying rare white matter disorders.
Multiple sclerosis; trial design
- Chataway J, Nicholas R, Todd S, Miller DH, Parsons N, Valdés-Márquez E, Stallard N, Friede T. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Multiple Sclerosis 2011; 17: 81-8
- Friede T, Parsons N, Stallard N Todd S, Valdés-Márquez E, Chataway J, Nicholas R. Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis. Statistics in Medicine (in press) 2011
- Chataway J. Progression is likely to occur earlier in young men with motor onset symptoms. JNNP 2010; 81: 944-5.
- Chataway J. The radiologically isolated syndrome. Practical Neurology 2010; 10: 271-7.
- Friede T, Nicholas R, Stallard N, Todd S, Parsons N, Valdés-Márquez E, Chataway J. Refinement of the Clinical Evaluation Scenario framework for assessment of competing development strategies with an application to Multiple Sclerosis. Drug Information Journal 2010; 44: 713-18
- Paisán-Ruiz C, Li A, Schneider SA, Holton JL, Johnson R, Kidd D, Chataway J, Bhatia KP, Lees AJ, Hardy J, Revesz T, Houlden H. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging 2010 e-print July
- Furby J, Hayton T, Altmann D, Brenner R, Chataway J, Smith KJ, Miller DH, Kapoor R. A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. J Neurol. 2010; 257 :1508-16.
- Kapoor R, Furby J, Hayton T, Smith K, Altmann D, Brenner R, Chataway J, Hughes RAC, Miller DH. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurology 2010; 9: 681-88
- Hilari K, Nothcott S, Roy P, Marshall J, Wiggins ED, Chataway J, Ames D. Psychological distress after stroke and aphasia: the first six months. Clinical Rehabilitation 2010; 24: 181-90
- Banerjee S, Biram R, Chataway J, Ames D. South Asian strokes: lessons from the St Mary's stroke database. QJM 2010; 103: 17-21
- Chataway J, Ali, A, O’Flynn N. Service development or research: make sure you know which game you are playing. London J Primary Care 2009;2:138-43
- Banerjee S, Natarajan I, Biram R, Sutton K, Ekeng G, Ames D, Chataway J. Fast-TIA: a prospective evaluation of a nurse-led anterior circulation TIA clinic. Postgrad Med J. 2009 85:637-42.
- Furby J, Hayton T, Altmann D, Brenner R, Chataway J, Smith KJ, Miller DH, Kapoor R. Different white matter lesion characteristics correlate with distinct grey matter abnormalities on magnetic resonance imaging in secondary progressive multiple sclerosis. Multiple Sclerosis 2009 Jun 15 (6) 687-94
- Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Hunter K, Tozer DJ, Miller DH, Kapoor R. Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. J Neurol. 2009; 256: 427-35
- Furby J, Hayton T, Anderson V, Altmann D, Brenner R, Chataway J, Hughes R, Smith K, Miller D, Kapoor R. Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Multiple Sclerosis 2008 Sep;14(8):1068-75
- Chataway J. When the MRI scan suggests MS, but the symptoms do not. JNNP 2008: 79: 112-13
- Tofaris GK, Revesz T, Jacques TS, Papacostas S, Chataway J. Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinico-pathological entity? Arch Neurol 2007:64; 280-2
- O’Riordan S, Stevens J, Chataway J. Spontaneous improvement of syringomyelia with deterioration of a Chiari type I malformation and new symptoms. Arch Neurol 2006:63;1328
- Chataway J, Porter B, Hobart JC, Heaney D, Riazi A, Thompson AJ. Home versus outpatient administration of intravenous steroids for multiple sclerosis relapses: a randomised controlled trial. Lancet Neurology 2006 (5) 565-71
- Carroll KAL and Chataway J. Understanding stroke. studentBMJ Sept 2006: 319-321
- Carroll KAL and Chataway J. Understanding stroke. studentBMJ Oct 2006: 364-368
- Parton A, Malhotra P, Nachev P, Ames D, Ball J, Chataway J, Husain M. Space re-exploration in hemispatial neglect. Neuroreport 2006; 17: 833-6
- Gale DP, Cobbold JF, Chataway J. Steroid-responsive functional B12 deficiency in association with Transcobalamin II polymorphism 776C>G. European Journal of Haematology 2006; 76: 75-78.
- Jindal R, Choong A, Arul D, Dhanji S, Chataway J, Cheshire NJW. Vascular Manifestations of Type IV Ehlers-Danlos Syndrome. Eur J Vasc Endovasc Surg. 2005 Aug; 30(2): 224-7
- J. Chataway, NWS Davies, S Farmer, RS Howard, EJ Thompson, KN Ward. Herpes simplex encephalitis: an audit of the use of laboratory diagnostic tests. QJM 2004 97: 325-330.
- Riazi A, Hobart JC, Porter B, Chataway J, Thompson AJ. Developing a measure of patients’ experiences of relapse management in multiple sclerosis. Multiple Sclerosis 2003;9: Suppl 1: S152.
- Robless P, Bicknell C, Chataway SJS, Cheshire N, Wolfe J. Stenosis and carotid endarterectomy. Lancet 2003; 361:1655
- Chataway SJS, Mander A, Robertson N, Sawcer S, Deans J, Fraser M, Broadley SA,Clayton D, Compston A. Multiple sclerosis in sibling pairs - analysis of 250 families. JNNP 2001; 71: 757-761
- Chataway SJS, Larner AJ, Kapoor R. Anti-GQ1b antibody status, magnetic resonance imaging and the nosology of Bickerstaff’s brainstem encephalitis. Eur J Neurol 2001; 8: 355-357
- Broadley SA, Sawcer SJ, Chataway SJS, Coraddu F, Coles A, Gray J, Roxburgh R, Clayton D, Compston A. No association between multiple sclerosis and the Notch3 gene responsible for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). JNNP 2001; 71: 97-99
- Reuber M, Zeidler M, Chataway SJS, Sadler M. Munchausen syndrome by phone. Lancet 2000; 356: 1358
- Feakes R, Sawcer S, Smillie B, Chataway SJS, Broadley S, Clayton D, Compston A. No evidence for the involvement of interleukin 2 or the immunoglobulin heavy chain cluster in determining genetic susceptibility to multiple sclerosis. JNNP 2000; 68: 679-680
- Broadley SA, Deans J, Chataway SJS, Sawcer S, Compston A. Multiple sclerosis and tonsillectomy: no evidence for an influence on the development of disease or clinical phenotype. Multiple Sclerosis 2000; 6: 121-123
- Chataway SJS, Stenning S, Blehan N, Grant R. Different outcome measures in randomised studies of malignant glioma can significantly alter the interpretation of time to progression: reanalysis of the MRC BR2 study. J Neuro-oncology 1999; 43: 87-92
- Chataway SJS, Sawcer S, Feakes R, Broadley SA, Gray J, Compston A. More evidence that founder effects exist in the European population. Eur J Hum Genetics 1999; 7: 623-624
- Chataway SJS, Sawcer S, Sherman D, Hobart M, Fernie B, Coraddu F, Feakes R, Broadley SA, Gray J, Jones HB, Clayton D, Goodfellow PN, Compston A. No evidence for association of multiple sclerosis with the complement factors C6 and C7. J Neuroimm 1999; 99: 150-156
- Chataway SJS, Sawcer S, Feakes R, Coraddu F, Broadley SA, Jones H, Clayton D, Gray J, Goodfellow PN, Compston A. A screen of candidates from the peaks of linkage: evidence for the involvement of myeloperoxidase in multiple sclerosis. J Neuroimm. 1999; 98: 208-213
- Chataway SJS, Sawcer S, Broadley SA, Jones H, Clayton D, Goodfellow PN, Compston A. Evidence that allelic variants of the spinocerebellar ataxia genes may contribute to multiple sclerosis susceptibility. Neurogenetics 1999; 2: 91-96
- Feakes R, Sawcer S, Chataway SJS, Gray J, Jones H, Clayton D, Goodfellow PN, Compston A. Exploring the dense mapping of a region of potential linkage in complex disease: an example in multiple sclerosis. Genet Epidemiol 1999; 17: 51-63
- Coraddu F, Sawcer S, Feakes R, Chataway SJS, Broadley SA, Jones HB, Clayton D, Gray J, Smith S, Taylor C, Goodfellow PN, Compston A. HLA typing in the United Kingdom multiple sclerosis genome screen. Neurogenetics 1998; 2: 24-33
- Feakes R, Chataway SJS, Sawcer S, Jones H, Clayton D, Goodfellow PN, Compston A. Susceptibility to multiple sclerosis and the immunoglobulin heavy chain cluster. Ann Neurol 1998; 44: 984
- Chataway SJS, Feakes R, Coraddu F, Gray J, Deans J, Fraser M, Robertson N, Broadley S, Jones H, Clayton D, Goodfellow P, Sawcer S, Compston A. The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen. Brain 1998; 121: 1869-1887
- Clyde Z, Chataway SJS, Signorini D, Gregor A, Grant R. Significant change in tests of neurological impairment in patients with brain tumours. J Neuro-oncology 1998; 39 : 81-90
- Chataway SJS, Mumford CR, Ironside J. Liquorice induced hypokalaemic myopathy. PostgradMedJ 1997; 836: 593-94
- Robertson NP, O’Riordan JI, Chataway SJS, Kingsley DPE, Miller DH, Clayton D, Compston, DAS. Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. Lancet 1997; 349: 1587-90
- Sawcer S, Jones HB,Feakes R, Gray J, Smalldon N, Chataway SJS, Robertson N,Clayton D, Goodfellow P, Compston DAS. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22 Nature Genetics 1996; 13: 464-68